ONDINE BIOMEDICAL INC.CDI
Ondine Biomedical Inc., a life-sciences company, engages in the development and commercialization of antimicrobial therapies in Canada and internationally. Its primary product is Steriwave, which enables rapid elimination of pathogens associated with healthcare-associated infections. In addition, the company offers a pipeline of products for various indications, including burns, ventilator tube, … Read more
ONDINE BIOMEDICAL INC.CDI (VF5) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, ONDINE BIOMEDICAL INC.CDI (VF5) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
ONDINE BIOMEDICAL INC.CDI - Net Assets Trend (None–None)
This chart illustrates how ONDINE BIOMEDICAL INC.CDI's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ONDINE BIOMEDICAL INC.CDI (None–None)
The table below shows the annual net assets of ONDINE BIOMEDICAL INC.CDI from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to ONDINE BIOMEDICAL INC.CDI's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
ONDINE BIOMEDICAL INC.CDI Competitors by Market Cap
The table below lists competitors of ONDINE BIOMEDICAL INC.CDI ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Vertoz Advertising Limited
NSE:VERTOZ
|
$32.29 Million |
|
FGV Holdings Bhd
KLSE:5222
|
$32.29 Million |
|
reAlpha Tech Corp. Common Stock
NASDAQ:AIRE
|
$32.30 Million |
|
Launch Technologies Co Ltd
TWO:8420
|
$32.31 Million |
|
CHINA MAPLE LE.ED.HD0005
F:CML1
|
$32.28 Million |
|
Ubon Bio Ethanol PCL
BK:UBE
|
$32.27 Million |
|
BANCA PROFILO
F:BPA
|
$32.26 Million |
|
Kluang Rubber Company Malaya
KLSE:2453
|
$32.26 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ONDINE BIOMEDICAL INC.CDI's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares ONDINE BIOMEDICAL INC.CDI's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently ONDINE BIOMEDICAL INC.CDI utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares ONDINE BIOMEDICAL INC.CDI's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ONDINE BIOMEDICAL INC.CDI (VF5) | €- | N/A | N/A | $32.28 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |